WS Value & Dossier GmbH
Your specialists for market access and reimbursement
How the German AMNOG process works
Value & Dossier GmbH advises pharmaceutical companies and biotechnology companies throughout the AMNOG process and on all matters relating to market access and reimbursement. Based on our long-standing expertise, we advise you on the development of the best strategy, the preparation of your benefit dossier for the G-BA assessment and the price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Your success is what drives us. We will make sure that your new product will be reimbursed in the best possible way.
Our Services
Strategic Market Access Consulting
German Benefit Assessment (AMNOG)
AMNOG price negotiations 
Reference pricing for pharmaceuticals
European Health Technology Assessment (EU-HTA)
European Reference Price Calculator
Reimbursement of Medical Devices
HTA Services“We offer individual and company-specific solutions focussing on the value of the product while implementing it accordingly in the required benefit dossiers.”
Your team of specialists from Value & Dossier
f. l. t. r.: Vanessa Henkel (M. Sc.), Dr. Angela Lammert, Dr. Sandra Kiehlmeier, Dr. Caroline Steinmetz, Dr. Jasmin Gömann, Hanna Klimek (M. Sc.), Christian Schneider, Dr. Willi Schnorpfeil
Recent Articles
Further specifications on the GKV-FinStG law
In their 2nd and 3rd reading, the German Parliament has decided further specifications of the new law on
Pharmabarometer Update
Have a look at our latest update of German price negotiations for drugs that went through the AMNOG
GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected
The German cabinet, the coalition group of ministers, has decided to introduce the draft bill on the financial
